This summary was created by AI, based on 12 opinions in the last 12 months.
Vertex Pharmaceuticals Inc. is receiving positive reviews from experts regarding its cystic fibrosis franchise and its potential for growth in other therapeutic areas. The stock has shown impressive gains and is considered to be a high-quality biopharma company with strong potential for long-term success. However, there are concerns about the stock being overvalued and recommendations to take profits. Overall, Vertex Pharmaceuticals Inc. is seen as a well-performing company with good momentum and a diverse product portfolio.
Even at this all time high don't sell. They're working on non-addictive painkillers
It's doing well, hitting new highs today. It's further along in its life cycle. Has a fine cystic fibrosis franchise. Shares are strong momentum, so he's staying in.
This drugmaker has a lock on MS and have new shots on pain management and other maladies. Lots going on. Up sharply this month.
Likes it, but she trimmed it because a lot of the good news from its pain medicine is now in the stock.
PPH, an ETF for pharma producers, is breaking out and near a record. VTX and Eli Lilly are leaders in this space and Vertex has a great product for Cystic Fibrosis therapeutics. It is growing well and not too expensive.
They're in the MS business, so will they expand beyond MS? HE's confident they will and have some hit drugs.
A high-quality biopharma with a strong cystic fibrosis drug. Are trying to get into other franchises like diabetes treatments. Will do well long-run. Trades at 23x with 11% earnings growth, so you can take some profits now. Had a good run, so take some money off the table.
Not too expensive. They report next week. They have good momentum and products.
Vertex Pharmaceuticals Inc. is a American stock, trading under the symbol VRTX-Q on the NASDAQ (VRTX). It is usually referred to as NASDAQ:VRTX or VRTX-Q
In the last year, 10 stock analysts published opinions about VRTX-Q. 7 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Vertex Pharmaceuticals Inc..
Vertex Pharmaceuticals Inc. was recommended as a Top Pick by on . Read the latest stock experts ratings for Vertex Pharmaceuticals Inc..
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
10 stock analysts on Stockchase covered Vertex Pharmaceuticals Inc. In the last year. It is a trending stock that is worth watching.
On 2024-10-07, Vertex Pharmaceuticals Inc. (VRTX-Q) stock closed at a price of $448.6.
Negative free cash flow to enter 2024, but it's turning positive. Shares are up 21% this year.